Our engineered AAV capsids were created to overcome key limitations in the first generation of gene therapies, including the seroprevalence of neutralizing antibodies, excessive liver tropism, and imperfect translation from preclinical model systems to human patients. Our capsids have undergone extensive structural engineering to reduce their antigenic footprint and detarget the liver while preserving key stabilizing motifs that support manufacturability. To help derisk clinical translation, these capsids were evolved through multiple species during development for improved cross-species compatibility.
